"The voice for cancer physicians and their patients in Massachusetts."

FDA approves brigatinib (Alunbrig) for ALK-positive metastatic NSCLC

02 Jun 2020 2:40 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved brigatinib (ALUNBRIG, Takeda) for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software